BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images, please do not report the images to the Image Problem Mailbox.

A14

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 :
C07D 215/14, A61K 31/33, 31/19, A61P 43/00, C07D 401/12, 401/14, 215/18, 405/12, 263/32, 213/30, 241/42, 277/24, 261/08, 271/06, 277/64

A1

(11) International Publication Number: **WO 00/64876**

(43) International Publication Date: 2 November 2000 (02.11.00)

(21) International Application Number: PCT/US00/11490

(22) International Filing Date: 28 April 2000 (28.04.00)

(30) Priority Data:
60/131,454 28 April 1999 (28.04.99) US

(71) Applicant *(for all designated States except US)*: AVENTIS PHARMACEUTICALS PRODUCTS INC. [US/US]; 500 Arcola Road, Collegeville, PA 19426 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: JAYYOSI, Zaid [FR/US]; 108 Cherrywood Court, Collegeville, PA 19426 (US). MCGEEHAN, Gerard, M. [US/US]; 1711 Spring House Road, Chester Springs, PA 19425 (US). KELLEY, Michael, F. [US/US]; 1086 Heartsease Drive, West Chester, PA 19382 (US). LABAUDINIERE, Richard, F. [FR/US]; 220 Richard Way, Collegeville, PA 19426 (US). ZHANG, Litao [US/US]; 456 Shakespere Drive, Collegeville, PA 19426 (US). CAULFIELD, Thomas, J. [US/US]; 362 Vista Drive, Phoenixville, PA 19460 (US). MINNICH, Anne [US/US]; 2107 Goodwin Lane, Montgomeryville, PA 19454 (US). BOBKO, Mark [US/US]; 526 Summercroft Drive, Exton, PA 19341 (US). MORRIS, Robert [US/US]; 125 Conestoga Road, Wayne, PA 19087 (US). GRONEBERG, Robert, D. [US/US]; 4173 Ironbridge Drive, Collegeville, PA 19426 (US). MCGARRY, Daniel, G. [GB/US]; Apt. 1148, 3000 Valley Forge Circle, King of Prussia, PA 19406 (US).

(74) Agents: OEHLER, Ross, J. et al.; Aventis Pharmaceuticals Products Inc., 500 Arcola Road, Collegeville, PA 19426 (US).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: TRI-ARYL ACID DERIVATIVES AS PPAR RECEPTOR LIGANDS

(57) Abstract

This invention is directed to triaryl acid derivatives of formula (I) and their pharmaceutical compositions as PPAR ligand receptor binders. The PPAR ligand receptor binders of this invention are useful as agonists or antagonists of the PPAR receptor. In formula (I), (a), (b), and (c) are independently aryl, fused arylcycloalkenyl, fused arylcycloalkyl, fused arylheterocyclenyl, fused arylheterocyclyl, heteroaryl, fused heteroarylcycloalkemyl, fused heteroarylcycloalkyl, fused heteroarylheterocyclenyl, or fused heteroarylheterocyclyl; A is –O–, –S–, –SO–, $-SO_2-$, $-NR_{13}-$, –C(O)–, $-N(R_{14})C(O)-$, $-C(O)N(R_{15})-$, $-N(R_{14})C(O)N(R_{15})-$, $-C(R_{14})=N-$, (d), (e), (f) a chemical bond, (g) or (h); B is –O–, –S–, –SO–, $-SO_2-$, $-NR_{17}-$, a chemical bond, ethynylene, –C(O)–, $-N(R_{18})C(O)-$, or $-C(O)NR_{18}-$; D is –O–, –S–, $-NR_{19}-$, a chemical bond, ethynylene, –C(O)–, $-N(R_{20})C(O)-$, or $-C(O)N(R_{20})-$; E is a chemical bond or an ethylene group; Z is $R_{21}O_2C-$, $R_{21}OC-$, cyclo-imide, –CN, $R_{21}O_2SHNCO-$, $R_{21}O_2SHN-$, $(R_{21})_2NCO-$, $R_{21}O$–2,4–thiazolidinedionyl, or tetrazolyl.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

What is claimed is:

1. A compound of formula I



(I)

wherein:



, , and are independently aryl, fused arylcycloalkenyl, fused arylcycloalkyl, fused arylheterocyclenyl, fused arylheterocyclyl, heteroaryl, fused heteroarylcycloalkenyl, fused heteroarylcycloalkyl, fused heteroarylheterocyclenyl, or fused heteroarylheterocyclyl;

A is -O-, -S-, -SO-, -SO_2-, -NR_{13}-, -C(O)-, -$N(R_{14})C(O)$-, -$C(O)N(R_{15})$-, -$N(R_{14})C(O)N(R_{15})$-, -$C(R_{14})$=N-, a chemical bond,





B is –O-, -S-, -SO-, -SO_2-, -NR_{17}-, a chemical bond, ethynylene, -C(O)-, -$N(R_{18})C(O)$-, or –$C(O)NR_{18}$-;

D is –O-, -S-, -NR_{19}-, a chemical bond, ethynylene, -$N(R_{20})C(O)$-, -C(O)-, or –$C(O)N(R_{20})$-;

E is a chemical bond or an ethylene group;

a is 0-4;

b is 0-4;

c is 0-4;

d is 0-5;

e is 0-4;

f is 0-6;

g is 1-4;

h is 1-4;

R_1, R_3, R_5, R_7, R_9, and R_{11}, are independently hydrogen, halogen, alkyl, carboxyl, alkoxycarbonyl or aralkyl;

R_2, R_4, R_6, R_8, R_{10} and R_{12}, are independently $-(CH_2)_q-X$;

q is 0-3;

X is hydrogen, halogen, alkyl, alkenyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, aralkyl, heteroaralkyl, hydroxy, alkoxy, aralkoxy, heteroaralkoxy, carboxyl, alkoxycarbonyl, tetrazolyl, acyl, acylHNSO$_2$-, -SR$_{23}$, Y^1Y^2N- or Y^3Y^4NCO-;

Y^1 and Y^2 are independently hydrogen, alkyl, aryl, aralkyl or heteroaralkyl, or one of Y^1 and Y^2 is hydrogen or alkyl and the other of Y^1 and Y^2 is acyl or aroyl;

Y^3 and Y^4 are independently hydrogen, alkyl, aryl, aralkyl or heteroaralkyl;

Z is $R_{21}O_2C$-, $R_{21}OC$-, cyclo-imide, -CN, $R_{21}O_2SHNCO$-, $R_{21}O_2SHN$-, $(R_{21})_2NCO$-, $R_{21}O$- 2,4-thiazolidinedionyl, or tetrazolyl; and

R_{19} and R_{21} are independently hydrogen, alkyl, aryl, cycloalkyl, or aralkyl;

R_{13}, R_{17}, R_{19} and R_{23} are independently $R_{22}OC$-, $R_{22}NHOC$-, hydrogen, alkyl, aryl, heteroaryl, cycloalkyl, heterocyclyl, heteroaralkyl, or aralkyl;

R_{14}, R_{15}, R_{16}, R_{18} and R_{20} are independently hydrogen, alkyl, aralkyl, carbonyl, or alkoxycarbonyl;

or R_{14}, and R_{15} taken together with the carbon and nitrogen atoms through which they are linked form a 5 or 6-membered azaheterocyclyl group; or

when a is 2-4, then vicinal R_1 radicals taken together with the carbon atoms to which the R_1 radicals are linked form an ethylene group;or

when b is 2-4, then vicinal R_3 radicals taken together with the carbon atoms to which the R_3 radicals are linked form an ethylene group; or

when c is 2-4, then vicinal R_5 radicals taken together with the carbon atoms to which the R_5 radicals are linked form an ethylene group; or

when d is 2-5, then vicinal R_7 radicals taken together with the carbon atoms to which the R_7 radicals are linked form an ethylene group; or

when e is 2-4, then vicinal R_9 radicals taken together with the carbon atoms to which the R_9 radicals are linked form an ethylene group; or

when f is 2-6, then vicinal R_{11} radicals taken together with the carbon atoms to which the R_{11} radicals are linked form an ethylene group; and

R_{22} is hydrogen, alkyl, aryl, heteroaryl, cycloalkyl, heterocyclyl, heteroaralkyl, or aralkyl; or a pharmaceutically acceptable salt thereof, an N-oxide thereof, a hydrate thereof or a solvate thereof.

2. A compound according to claim 1 wherein 

is optionally substituted aryl, optionally substituted azaheteroaryl, or optionally substituted fused arylheterocyclenyl; 

is optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted fused arylheterocyclenyl; and 

is optionally substituted aryl, optionally substituted heteroaryl, optionally substituted fused arylheterocyclalkyl or optionally substituted fused arylheterocyclenyl.

3. A compound according to claim 1 wherein a = 1 or 2; R_1 and R_2 is hydrogen; A is a chemical bond; and b = 0.

4. A compound according to claim 1 wherein a = 0; A is 

; R_{15} and R_{16} are hydrogen; g is 1, 2, or 3; and b = 0.

5. A compound according to claim 1 wherein a = 0; A is $-NR_{13}-$, b = 1, R_3 and R_4 are hydrogen.

6. A compound according to claim 1 wherein a = 2; vicinal R_1 radicals taken together with the carbon atoms to which the R_1 radicals are linked form an ethylene group; R_2 is hydrogen; A is a chemical bond; and b=0.

7. A compound according to claim 1 wherein a = 1, 2 or 3; R_1 and R_2 are hydrogen; A is -O-; and b = 0.

8. A compound according to claim 1 wherein a = 1; R_1, R_2, R_3 and R_4 are hydrogen; A is -O-; and b = 1.

9. A compound according to claim 1 wherein c = 1 or 2; R_5 and R_6 are hydrogen or alkyl; B is a chemical bond; and d = 0.

10. A compound according to claim 1 wherein c = 2; vicinal R_5 radicals taken together with the carbon atoms to which the R_5 radicals are linked form an ethylene group; R_6 is hydrogen; B is a chemical bond; and d=0.

11. A compound according to claim 1 wherein c = 0 or 1; R_5 and R_6 are hydrogen; B is –O-; and d = 0 or 1.

12. A compound according to claim 1 wherein c = 0; B is –C(O)- or $-S(O)_2-$; d = 1 and R_7 and R_8 are independently hydrogen or alkyl.

13. A compound according to claim 1 wherein e = 0; f = 0; D and E is a chemical bond; Z is $R_{21}O_2SHNCO-$, and R_{21} is phenyl.

14. A compound according to claim 1 wherein e = 0; f = 0 or 1; D and E is a chemical bond; Z is tetrazolyl, NH_2CO- or $-CO_2R_{21}$; and R_{21} is hydrogen or lower alkyl.

15. A compound according to claim 1 wherein e = 0; f = 0 or 1; D is –O- or a chemical bond; E is a chemical bond; and Z is tetrazolyl, NH_2CO- or $-CO_2R_{21}$; and R_{21} is hydrogen or lower alkyl.

16. A compound according to claim 1 wherein e = 0; f = 1; D is –O- or a chemical bond; E is a chemical bond; R_{11} and R_{12} are hydrogen or alkyl; and Z is tetrazolyl, NH_2CO- or $-CO_2R_{21}$; and R_{21} is hydrogen or lower alkyl.

17. A compound according to claim 1 wherein e = 2, then vicinal R_9 radicals taken together with the carbon atoms to which the R_9 radicals are linked form an ethylene group; f = 0; D and E is a chemical bond; and Z is $-CO_2R_{21}$; and R_{21} is hydrogen.

18. A compound according to claim 1 wherein e = 0; f = 3; D is -O-; E is a chemical bond; R_{11} and R_{12} are hydrogen or alkyl, or at least one of R_{11} is carboxyl or alkoxycarbonyl; Z is tetrazolyl, or $-CO_2R_{21}$; and R_{21} is hydrogen or lower alkyl.

19. A compound according to claim 1 wherein e = 0; f = 1, 2, or 3; D is -C(O)-; E is a chemical bond; R_{11} and R_{12} are hydrogen or alkyl; Z is tetrazolyl or $-CO_2R_{21}$; and R_{21} is hydrogen or lower alkyl.

20. A compound according to claim 1 wherein 

is an optionally substituted quinolinyl, quinoxalinyl, quinazolinyl, isoquinolinyl, *N*-alkyl-quinolin-4-onyl, quinazolin-4-onyl, benzoxazolyl, benzimidazolyl, benzothiazolyl, benzofuranyl, benzothiophenyl, indolinyl oxazolyl, thiazolyl, oxadiazolyl isoxazolyl, imidazolyl, pyrazol-yl, thiadiazolyl, triazolyl, pyridyl pyrimidinyl, pyrazinyl, pyridazinyl, phenyl, or napthalenyl group, wherein the substituent is a

ring system substituent as defined herein, more preferably a substituent selected from the group consisting of phenyl, substituted-phenyl, thienyl, substituted thienyl, cycloalkyl, lower alkyl, branched alkyl, fluoro, chloro, alkoxy, aralkyloxy, trifluoromethyl and trifluoromethyloxy.

21. A compound according to claim 1 wherein 

is unsubstituted quinolin-2-yl, 3-substituted quinolin-2-yl, 4-substituted quinolin-2-yl, 6-substituted quinolin-2-yl or 7 substituted quinolin-2-yl; an unsubstituted quinozalin-2-yl, 3-substituted quinozalin-2-yl, 6-substituted quinozalin-2-yl or 3,6-disubstituted quinozalin-2-yl; unsubstituted quinazolin-2-yl, 4-substituted quinazolin-2-yl or 6-substituted quinazolin-2-yl; unsubstituted isoquinolin-3-yl, 6-substituted isoquinolin-3-yl or 7-substituted isoquinolin-3-yl; 3-substituted-quinazolin-4-on-2-yl; *N*-substituted quinolin-4-on-2-yl; 2-substituted-oxazol-4-yl or 2,5 disubstituted-oxazol-4-yl; 4-substituted oxazol-2-yl or 4,5-disubstituted-oxazol-2-yl; 2-substituted thiazol-4-yl or 2,5-disubstituted thiazol-4-yl; 4-substituted thiazol-2-yl or 4,5-disubstituted-thiazol-2-yl; 5-substituted-[1,2,4]oxadiazol-3-yl; 3-substituted-[1,2,4] oxadiazol-5-yl; 5-substituted-imidazol-2-yl or 3,5-disubstituted-imidazol-2-yl; 2-substituted-imidazol-5-yl or 2,3-disubstituted-imidazol-5-yl; 3-substituted-isoxazol-5-yl; 5-substituted-isoxazol-3-yl; 5-substituted-[1,2,4] thiadiazol-3-yl; 3-substituted-[1,2,4]-thiadiazol-5-yl; 2-substituted-[1,3,4]-thiadiazol-5-yl; 2-substituted-[1,3,4]-oxadiazol-5-yl; 1-substituted-pyrazol-3-yl; 3-substituted-pyrazol-5-yl; 3-substituted-[1,2,4]-triazol-5-yl; 1-substituted-[1,2,4]-triazol-3-yl; 3-substituted pyridin-2-yl, 5-substituted pyridin-2-yl, 6-substituted pyridin-2-yl or 3,5-disubstituted pyridin-2-yl; 3-substituted pyrazin-2-yl, 5-substituted pyrazin-2-yl, 6-substituted pyrazin-2-yl or 3,5 disubstituted-pyrazin-2-yl; 5-substituted pyrimidin-2-yl or 6-substituted-pyrimidin-2-yl; 6-substituted-pyridazin-3-yl or 4,6-disubstituted-pyridazin-3-yl; unsubstituted napthalen-2-yl, 3-substituted napthalen-2-yl, 4-substituted napthalen-2-yl, 6-substituted napthalen-2-yl or 7 substituted napthalen-2-yl; 2-substituted phenyl, 4-substituted phenyl or 2,4-disubstituted phenyl; unsubstituted -benzothiazol-2-yl or 5-substituted-benzothiazol-2-yl; unsubstituted benzoxazol-2yl or 5-substituted-benzoxazol-2yl; unsubstituted -benzimidazol-2-yl or 5-substituted-benzimidazol-2-yl; unsubstituted -thiophen-2yl, 3-substituted -thiophen-2yl, 6-substituted -thiophen-2yl or 3,6-disubstituted-thiophen-2yl; unsubstituted -benzofuran-2-y, 3-substituted-benzofuran-2-yl, 6-substituted-benzofuran-2-yl or 3,6-disubstituted-benzofuran-2-yl; 3-substituted-benzofuran-6-yl or 3,7-disubstituted-benzofuran-6-yl, wherein the substituent is a ring system substituent.

22 A compound according to claim 21 wherein  is substituted by a substituent selected from the group consisting of phenyl, substituted-phenyl, thienyl, substituted thienyl, cycloalkyl, lower alkyl, branched alkyl, fluoro, chloro, alkoxy, aralkyloxy, trifluoromethyl and trifluoromethyloxy.

23. A compound according to claim 1 wherein R_1 and R_2 are hydrogen; a = 1; A is –O-; and b = 0.

24. A compound according to claim 1 wherein R_1 and R_2 are hydrogen; a = 2; A is –O-; and b = 0.

25. A compound according to claim 1 wherein a = 0; A is –O- or $-NR_{13}-$; R_{13} is hydrogen or alkyl; R_3 and R_4 are both independently hydrogen; and b = 1.

26. A compound according to claim 1 wherein a = 0; A is –O- or $-NR_{13}-$; R_{13} is hydrogen or alkyl; R_3 and R_4 are both independently hydrogen; b = 1; and  is 3-substituted quinolin-2-yl, 4-substituted quinolin-2-yl, 6-substituted quinolin-2-yl, 7 substituted quinolin-2-yl, unsubstituted quinoxalin-2-yl, 3-substituted quinoxalin-2-yl, 6-substituted quinoxalin-2-yl, 3,6-disubstituted quinoxalin-2-yl, unsubstituted quinazolin-2-yl, 4-substituted quinazolin-2-yl, 6-substituted quinazolin-2-yl, unsubstituted isoquinolin-3-yl, 6-substituted isoquinolin-3-yl, 7-substituted isoquinolin-3-yl, 4-substituted oxazol-2-yl, 4,5-disubstituted-oxazol-2-yl, 4-substituted-thiazol-2-yl, 4,5-disubstituted-thiazol-2-yl, 5-substituted -imidazol-2-yl, 3,5-disubstituted-imidazol-2-yl, 1-substituted-pyrazol-3-yl, 3-substituted-pyrazol-5-yl, 3-substituted pyridin-2-yl, 5-substituted pyridin-2-yl, 6-substituted pyridin-2-yl or 3,5-disubstituted pyridin-2-yl, 3-substituted pyrazin-2-yl, 5-substituted pyrazin-2-yl, 6-substituted pyrazin-2-yl, 3,5 disubstituted-pyrazin-2-yl, 5-substituted pyrimidin-2-yl, 6-substituted-pyrimidin-2-yl, 6-substituted-pyridazin-3-yl, 4,6-disubstituted-pyridazin-3-yl, unsubstituted-benzothiazol-2-yl, 5-substituted-benzothiazol-2-yl, unsubstituted-benzoxazol-2-yl, 5-substituted-benzoxazol-2-yl, unsubstituted benzimidazol-2-yl, 5-substituted-benzimidazol-2-yl, 3-substituted-benzofuran-6-yl or 3,7-disubstituted-benzofuran-6-yl.

27. A compound of formula (Ia)



(Ia)

wherein:



and are independently aryl, fused arylcycloalkenyl, fused arylcycloalkyl, fused arylheterocyclenyl, fused arylheterocyclyl, heteroaryl, fused heteroarylcycloalkenyl, fused heteroarylcycloalkyl, fused heteroarylheterocyclenyl, or fused heteroarylheterocyclyl;

A is -O-, -S-, -SO-, $-SO_2$-, $-NR_{13}$-, -C(O)-, $-N(R_{14})C(O)$-, $-C(O)N(R_{15})$-, $-N(R_{14})C(O)N(R_{15})$-, $-C(R_{14})=N$-, a chemical bond,



B is –O-, -S-, -SO-, $-SO_2$-, $-NR_{17}$-, a chemical bond, ethynylene, -C(O)-, $-N(R_{18})C(O)$-, or $-C(O)NR_{18}$-;

D is –O-, -S-, $-NR_{19}$-, a chemical bond, ethynylene, $-N(R_{20})C(O)$-, -C(O)-, or $-C(O)N(R_{20})$-;

E is a chemical bond or an ethylene group;

a is 0-4;

b is 0-4;

c is 0-4;

d is 0-5;

e is 0-4;

f is 0-6;

g is 1-4;

h is 1-4;

R_1, R_3, R_5, R_7, R_9, and R_{11}, are independently hydrogen, halogen, alkyl, carboxyl, alkoxycarbonyl or aralkyl;

R_2, R_4, R_6, R_8, R_{10} and R_{12}, are independently $-(CH_2)_q-X$;

q is 0-3;

X is hydrogen, halogen, alkyl, alkenyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, aralkyl, heteroaralkyl, hydroxy, alkoxy, aralkoxy, heteroaralkoxy, carboxyl, alkoxycarbonyl, tetrazolyl, acyl, acylHNSO$_2$-, -SR$_{23}$, Y^1Y^2N- or Y^3Y^4NCO-;

Y^1 and Y^2 are independently hydrogen, alkyl, aryl, aralkyl or heteroaralkyl, or one of Y^1 and Y^2 is hydrogen or alkyl and the other of Y^1 and Y^2 is acyl or aroyl;

Y^3 and Y^4 are independently hydrogen, alkyl, aryl, aralkyl or heteroaralkyl;

Z is $R_{21}O_2C$-, $R_{21}OC$-, cyclo-imide, -CN, $R_{21}O_2SHNCO$-, $R_{21}O_2SHN$-, $(R_{21})_2NCO$-, $R_{21}O$- 2,4-thiazolidinedionyl, or tetrazolyl;

R' and R" are ring system substituents;

R_{19} and R_{21} are independently hydrogen, alkyl, aryl, cycloalkyl, or aralkyl;

R_{13}, R_{17}, R_{19} and R_{23} are independently $R_{22}OC$-, $R_{22}NHOC$-, hydrogen, alkyl, aryl, heteroaryl, cycloalkyl, heterocyclyl, heteroaralkyl, or aralkyl;

R_{14}, R_{15}, R_{16}, R_{18} and R_{20} are independently hydrogen, alkyl, aralkyl, carbonyl, or alkoxycarbonyl;

or R_{14}, and R_{15} taken together with the carbon and nitrogen atoms through which they are linked form a 5 or 6-membered azaheterocyclyl group; or

when a is 2-4, then vicinal R_1 radicals taken together with the carbon atoms to which the R_1 radicals are linked form an ethylene group;or

when b is 2-4, then vicinal R_3 radicals taken together with the carbon atoms to which the R_3 radicals are linked form an ethylene group; or

when c is 2-4, then vicinal R_5 radicals taken together with the carbon atoms to which the R_5 radicals are linked form an ethylene group; or

when d is 2-5, then vicinal R_7 radicals taken together with the carbon atoms to which the R_7 radicals are linked form an ethylene group; or

when e is 2-4, then vicinal R_9 radicals taken together with the carbon atoms to which the R_9 radicals are linked form an ethylene group; or

when f is 2-6, then vicinal R_{11} radicals taken together with the carbon atoms to which the R_{11} radicals are linked form an ethylene group; and

R_{22} is hydrogen, alkyl, aryl, heteroaryl, cycloalkyl, heterocyclyl, heteroaralkyl, or aralkyl; or

a pharmaceutically acceptable salt thereof, an N-oxide thereof, a hydrate thereof or a solvate thereof.

28. A compound according to claim 27

wherein



and


are independently aryl, fused arylcycloalkenyl, fused arylcycloalkyl, fused arylheterocyclenyl, fused arylheterocyclyl, heteroaryl, fused heteroarylcycloalkenyl, fused heteroarylcycloalkyl, fused heteroarylheterocyclenyl, or fused heteroarylheterocyclyl;

c+d = 1 or 2;

B is –O-;

R_5, R_6, R_7, R_8 are independently hydrogen;

e = 0;

f = 0;

D and E are a chemical bond;

Z is $R_{21}O_2C$-, $R_{21}OC$-, cyclo-imide, -CN, $R_{21}O_2SHNCO$-, $R_{21}O_2SHN$-, $(R_{21})_2NCO$-, $R_{21}O$- 2,4-thiazolidinedionyl, or tetrazolyl;

R' is lower alkyl, halo, alkoxy, aryloxy or aralkyl; and

R" is lower alkyl or halo.

29. A compound according to claim 27 wherein



and


are independently aryl, fused arylcycloalkenyl, fused arylcycloalkyl, fused arylheterocyclenyl, fused arylheterocyclyl, heteroaryl, fused heteroarylcycloalkenyl, fused heteroarylcycloalkyl, fused heteroarylheterocyclenyl, or fused heteroarylheterocyclyl;

c+d = 1 or 2;

B is –O-;

R_5, R_6, R_7, R_8 are independently hydrogen;

e = 0;

f = 0;

D and E are a chemical bond;

Z is $-CO_2H$;

R' is lower alkyl, halo, alkoxy, aryloxy or aralkyl; and

R" is lower alkyl or halo.

30. A compound according to claim 27 wherein

a = 0-2;

b = 0-1;

A is -O- or $-NR_{13}$-;

c+d = 1 or 2;

B is -O-;

R_1, R_2, R_3, R_4 R_5, R_6, R_7, and R_8 are independently hydrogen;

R_{13} is hydrogen, $R_{22}OC$-, or alkyl;

e = 0;

f = 0;

D and E are a chemical bond;

Z is $-CO_2H$;

R' is lower alkyl, halo, alkoxy, aryloxy or aralkyl; and

R" is lower alkyl or halo.

31. A compound according to claim 27 wherein

a = 1 or 2;

A is -O-;

b = 0;

R_1, R_2, R_7 and R_8 are independently hydrogen;

is optionally substituted phenyl;

c = 0;

B is -O-;

d = 1;

e = 0;

f = 0;

D and E are a chemical bond;

R' is hydrogen, halo or benzyloxy;

R" is lower alkyl, preferably methyl;

Z is $-CO_2H$.

32. A compound according to claim 27 wherein:

a = 1 or 2;

A is -O-;

b = 0;

R_1, R_2, R_5 and R_6 are independently hydrogen;



is optionally substituted phenyl;

c = 1;

B is -O-;

d = 0;

e = 0;

f = 0;

D and E are a chemical bond;

R' is hydrogen, halo or benzyloxy;

R" is lower alkyl, preferably methyl;

Z is $-CO_2H$.

33. A compound according to claim 27 wherein:

a = 1 or 2;

A is -O-;

b = 0;

R_1, R_2, R_7, R_8, R_{11} and R_{12} are independently hydrogen;



is optionally substituted phenyl;

c = 0;

B is -O-;

d = 1;

e = 0;

f = 1;

D and E are a chemical bond;

R' is halo;

R" is lower alkyl, preferably methyl;

Z is $-CO_2H$.

34. A compound according to claim 27 wherein:

a = 1;

A is -O-;

b = 0;

c = 0-1;

B is -O-;

d = 0 or 1, wherein c+d = 1 or 2;

e = 0;

f = 0;

D and E are a chemical bond;

R' is hydrogen, aralkoxy, or halo;

R" is lower alkyl, preferably methyl;

Z is $-CO_2H$.

35. A compound according to claim 27 wherein:

a = 1;

A is -O-;

b = 0;

c = 0;

B is -O-;

d = 1;

e = 0;

f = 0;

D and E are a chemical bond;

R' is hydrogen;

R" is lower alkyl;

Z is $-CO_2H$.

36. A compound according to claim 27 wherein:



and



are aryl or heteroaryl;

a = 1;

A is -O-;

b = 0;

c = 0;

B is -O-;

d = 1;

e = 0;

f = 0;

D and E are a chemical bond;

R' is hydrogen;

R" is lower alkyl;

Z is $-CO_2H$.

37. A compound according to claim 27 wherein:

is optionally substituted azaheteroaryl;



is optionally substituted phenyl;

a = 1;

A is -O-;

b = 0;

c = 0;

B is -O-;

d = 1;

e = 0;

f = 0;

D and E are a chemical bond;

R' is hydrogen;

R" is lower alkyl;

Z is CO_2H.

38. A compound according to claim 27 wherein:



is optionally substituted quinolinyl, or a 5-membered heteroaryl group wherein the heteroaryl group is substituted by optionally substituted phenyl or optionally substituted cyclohexyl;

is optionally substituted phenyl;

a = 1;

A is –O-;

b = 0;

c = 0;

B is –O-;

d = 1;

e = 0;

f = 0;

D and E are a chemical bond;

R' is hydrogen;

R" is lower alkyl;

Z is CO_2H.

39. A compound according to claim 1 selected from the group




;


;

;

;


;

;

;


;

;

;


;

;

;


;

;


;

;

;

;

;

;

;

;

;

;

;

;

;

;

;


;

;

;

;

;

;

;

;

;

;

;

;

;

;

5


;

;

;

;

;

;

;

;

;

;

;

;

;

;

5


;

;

;

;

;

;

;

;

;

;

;

;

;

;


;


;


;


;


;


;


;


;


;


;


;


;


;


;

;

;

;

;

;

;

;

;

;

;

;

;

;

5


;

;

;

;

;

;

5


;

;

;

;

;

;

;

;





















































;

HCl
;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;









and

40. A compound according to claim 1 selected from the group consisting of









5




;

;

;

;

;

;

;

;

;

;

;

;


5 and

41. A compound according to claim 1 selected from the group consisting of


;

;

;

;

10


;

;


;

;


; and

42. A compound according to claim 1 selected from the group consisting of


;

;

;

;

and

43. A compound according to claim 1 selected from the group consisting of


;

;

;

;

;

;

and

44. A compound according to claim 1 selected from the group consisting of



; and

45. A compound according to claim 1 selected from the group consisting of


;

; and


46. A compound according to claim 1 selected from the group consisting of


;

; and


47. A compound according to claim 1 selected from the group consisting of



48. A compound according to claim 1 of the formula



49. A pharmaceutical composition comprising a pharmaceutically acceptable amount of the compound according to claim 1 and a pharmaceutically acceptable carrier.

50. A method of treating a patient suffering from a physiological disorder capable of being modulated by a compound according to claim 1 having PPAR ligand binding activity, comprising administering to the patient a pharmaceutically effective amount of the compound, or a pharmaceutically acceptable salt thereof.

51. A method according to claim 50 wherein the disease is associated with a physiological detrimental blood level of insulin, glucose, free fatty acids (FFA), or triclycerides.

52. The method according to claim 51, wherein the physiological disorder is hyperglycemia.

53. The method according to claim 52, wherein the hyperglycemia is diabetes

54. The method according to claim 52, wherein the hyperglycemia is Type II diabetes.

55. The method according to claim 51, wherein the physiological disorder is hyperinsulinism.

56. The method according to claim 55, wherein the hyperinsulinism is Syndrome X.

57. The method according to claim 51, wherein the physiological disorder is insulin resistance.

58. The method according to claim 51, wherein the physiological disorder is cardiovascular condition.

59. The method according to claim 58, wherein the cardiovascular condition is atherosclerosis.

60. The method according to claim 51, wherein the physiological disorder is hyperlipidemia.

61. The method according to claim 51, wherein the physiological disorder is hypertension.

62. The method according to claim 51, wherein the physiological disorder is an eating disorder.

63. The method according to claim 50 wherein the mediating is agonistic.

64. The method according to claim 50 wherein the mediating is antagonistic.

65. A method for mediating the activity of PPAR-γ receptor comprising contacting said PPAR-γ receptor with a compound of according to claim 1.

66. A pharmaceutical composition comprising a pharmaceutically acceptable amount of the compound according to claim 27 and a pharmaceutically acceptable carrier.

67. A method of treating a patient suffering from a physiological disorder capable of being modulated by a compound according to claim 27 having PPAR ligand binding activity, comprising administering to the patient a pharmaceutically effective amount of the compound, or a pharmaceutically acceptable salt thereof.

68. A method according to claim 67 wherein the disease is associated with a physiological detrimental blood level of insulin, glucose, free fatty acids (FFA), or triclycerides.

69. The method according to claim 67, wherein the physiological disorder is hyperglycemia.

70. The method according to claim 69, wherein the hyperglycemia is diabetes

71. The method according to claim 69, wherein the hyperglycemia is Type II diabetes.

72. The method according to claim 67, wherein the physiological disorder is hyperinsulinism.

73. The method according to claim 72, wherein the hyperinsulinism is Syndrome X.

74. The method according to claim 67, wherein the physiological disorder is insulin resistance.

75. The method according to claim 67, wherein the physiological disorder is cardiovascular disorder.

76. The method according to claim 75, wherein the cardiovascular disorder is atherosclerosis.

77. The method according to claim 67, wherein the physiological disorder is hyperlipidemia.

78. The method according to claim 67, wherein the physiological disorder is hypertension.

79. The method according to claim 67, wherein the physiological disorder is an eating disorder.

80. The method according to claim 67 wherein the mediating is agonistic.

81. The method according to claim 67 wherein the mediating is antagonistic.

82. A method for mediating the activity of PPAR receptor comprising contacting said PPAR receptor with a compound of according to claim 27.

83. A method of treating a patient suffering from a physiological disorder capable of being modulated by a compound having PPARα and PPARγ ligand binding activity, comprising administering to the patient a pharmaceutically effective amount of the compound, or a pharmaceutically acceptable salt thereof, wherein said compound is of the formula



84. A method of treating a patient suffering from a physiological disorder capable of being modulated by a compound having PPARα ligand binding activity, comprising administering to the patient a pharmaceutically effective amount of the compound, or a pharmaceutically acceptable salt thereof, wherein said compound is selected from the group consisting of


;

;

;

;

;

;
and


85. A method of treating a patient suffering from a physiological disorder capable of being modulated by a compound having PPARδ ligand binding activity, comprising administering to the patient a pharmaceutically effective amount of the compound, or a pharmaceutically acceptable salt thereof, wherein said compound is of the formula:



86. A method of treating a patient suffering from a physiological disorder capable of being modulated by a compound having PPARα and PPARδ ligand binding activity, comprising administering to the patient a pharmaceutically effective amount of the compound, or a

pharmaceutically acceptable salt thereof, wherein said compound is selected from the group consisting of:





; ; and

87. A method of treating a patient suffering from a physiological disorder capable of being modulated by a compound having PPARδ and PPARγ ligand binding activity, comprising administering to the patient a pharmaceutically effective amount of the compound, or a pharmaceutically acceptable salt thereof, wherein said compound is selected from the group consisting of:




; and

88. A method of treating a patient suffering from a physiological disorder capable of being modulated by a compound having PPARγ ligand binding activity, comprising administering to the patient a pharmaceutically effective amount of the compound, or a pharmaceutically acceptable salt thereof, wherein said compound is selected from the group consisting of:





; ; and

INTERNATIONAL SEARCH REPORT

Internation. pplication No
PCT/US 00/11490

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07D215/14 A61K31/33 A61K31/19 A61P43/00 C07D401/12
C07D401/14 C07D215/18 C07D405/12 C07D263/32 C07D213/30
C07D241/42 C07D277/24 C07D261/08 C07D271/06 C07D277/64

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C07D A61K A61P C07C

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 97 27857 A (MERCK & CO., INC.) 7 August 1997 (1997-08-07) * complete document *	1,49,66, 82
X	WO 98 27974 A (MERCK & CO., INC.) 2 July 1998 (1998-07-02) * complete document *	1,49,66, 82
X	WO 97 31907 A (GLAXO GROUP LTD.) 4 September 1997 (1997-09-04) * complete document *	1,49,66, 82
X	WO 97 28149 A (MERCK & CO., INC.) 7 August 1997 (1997-08-07) * complete document *	1,49,66, 82

-/--

[X] Further documents are listed in the continuation of box C.

[X] Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
21 September 2000	04/10/2000

Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Rijswijk Tel. (+31–70) 340–2040, Tx. 31 651 epo nl, Fax: (+31–70) 340–3016	Van Bijlen, H

Form PCT/ISA/210 (second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

Internatior. pplication No
PCT/US 00/11490

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07D263/58 C07D215/38 C07D215/20 C07D413/04 C07D409/12
C07D213/61 C07D401/06 C07D239/74 C07D215/60 C07C63/00
C07C57/03

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 97 24331 A (LABORATORIOS MENARINI S.A.) 10 July 1997 (1997-07-10) * complete document * ---	1,49
X	WO 99 07357 A (ONO PHARMACEUTICAL CO.,LTD.) 18 February 1999 (1999-02-18) * complete document * ---	1,49,66, 82
X	WO 99 08501 A (DR. REDDY'S RESEARCH FOUNDATION) 25 February 1999 (1999-02-25) * complete document * ---	1,49,66, 82
X	WO 89 04303 A (RORER INTERNATIONAL (OVERSEAS) INC.) 18 May 1989 (1989-05-18) * complete document * ---	1,49
	-/--	

[X] Further documents are listed in the continuation of box C.

[X] Patent family members are listed in annex.

° Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
21 September 2000	

Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Rijswijk Tel. (+31–70) 340–2040, Tx. 31 651 epo nl, Fax: (+31–70) 340–3016	Van Bijlen, H

2

Form PCT/ISA/210 (second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

International application No
PCT/US 00/11490

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 89 05294 A (LEO PHARMACEUTICAL PRODUCTS LTD.) 15 June 1989 (1989-06-15) * complete document *	1,49
X	WO 89 12629 A (RORER INTERNATIONAL (OVERSEAS) INC.) 28 December 1989 (1989-12-28) * complete document *	1,49
X	WO 92 22533 A (THE UPJOHN COMPANY) 23 December 1992 (1992-12-23) * complete document *	1,49
X	EP 0 643 045 A (CIBA-GEIGY AG) 15 March 1995 (1995-03-15) * complete document *	1,49
P,X	WO 99 20275 A (RHÔNE-POULENC RORER PHARMACEUTICALS INC.) 29 April 1999 (1999-04-29) * complete document *	1,49,66, 82

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 1-88 (partially)

The initial phase of the search revealed a very large number of documents relevant to the issue of novelty. So many documents were retrieved that it is impossible to determine which parts of the claim(s) may be said to define subject-matter for which protection might legitimately be sought (Article 6 PCT).
For these reasons it appears impossible to execute a meaningful search and/or to issue a complete search report over the whole breadth of the above mentioned claims.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Internatio. Application No
PCT/US 00/11490

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9727857 A	07-08-1997	AU 1856997 A	22-08-1997
		AU 719146 B	04-05-2000
		AU 2250797 A	22-08-1997
		CA 2245524 A	07-08-1997
		EP 0904079 A	31-03-1999
		WO 9728149 A	07-08-1997
		US 5859051 A	12-01-1999
WO 9827974 A	02-07-1998	AU 719663 B	11-05-2000
		AU 5615298 A	17-07-1998
		EP 0948327 A	13-10-1999
		AU 1856997 A	22-08-1997
		WO 9728149 A	07-08-1997
WO 9731907 A	04-09-1997	AP 780 A	22-11-1999
		AU 717699 B	30-03-2000
		AU 2093597 A	16-09-1997
		BG 102792 A	31-08-1999
		BR 9707786 A	27-07-1999
		CA 2247443 A	04-09-1997
		CN 1218460 A	02-06-1999
		CZ 9802750 A	13-01-1999
		EP 0888317 A	07-01-1999
		HR 970110 A	30-04-1998
		JP 2000507216 T	13-06-2000
		NO 983940 A	27-10-1998
		PL 328871 A	01-03-1999
		SK 116398 A	13-04-1999
WO 9728149 A	07-08-1997	AU 1856997 A	22-08-1997
		AU 721452 B	06-07-2000
		AU 2115997 A	22-08-1997
		CA 2245529 A	07-08-1997
		EP 0888278 A	07-01-1999
		WO 9728115 A	07-08-1997
		AU 712607 B	11-11-1999
		AU 1858197 A	22-08-1997
		CA 2244831 A	07-08-1997
		EP 1011651 A	28-06-2000
		JP 2000504021 T	04-04-2000
		WO 9727847 A	07-08-1997
		AU 719146 B	04-05-2000
		AU 2250797 A	22-08-1997
		CA 2245524 A	07-08-1997
		EP 0904079 A	31-03-1999
		WO 9727857 A	07-08-1997
		AU 708055 B	29-07-1999
		AU 1856397 A	22-08-1997
		EP 0882029 A	09-12-1998
		WO 9728137 A	07-08-1997
		US 5859051 A	12-01-1999
		ZA 9700824 A	30-10-1998
		US 5847008 A	08-12-1998
		AU 719663 B	11-05-2000
		AU 5615298 A	17-07-1998
		EP 0948327 A	13-10-1999
		WO 9827974 A	02-07-1998

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No
PCT/US 00/11490

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9724331 A	10-07-1997	ES 2117551 A	01-08-1998
		AU 1378397 A	28-07-1997
		EP 0874826 A	04-11-1998
WO 9907357 A	18-02-1999	AU 8559598 A	01-03-1999
WO 9908501 A	25-02-1999	AU 1120599 A	08-03-1999
WO 8904303 A	18-05-1989	US 4920133 A	24-04-1990
		AU 635196 B	18-03-1993
		AU 2719888 A	01-06-1989
		EP 0395697 A	07-11-1990
		JP 3500885 T	28-02-1991
		MX 9203773 A	01-07-1992
		US 5051427 A	24-09-1991
WO 8905294 A	15-06-1989	AT 110364 T	15-09-1994
		AU 2611888 A	05-07-1989
		AU 617386 B	28-11-1991
		CA 1336602 A	08-08-1995
		DE 3851232 D	29-09-1994
		DE 3851232 T	02-02-1995
		DK 118390 A	14-05-1990
		EP 0420844 A	10-04-1991
		ES 2011919 A	16-02-1990
		GR 1000422 B	30-06-1992
		IE 64473 B	09-08-1995
		JP 3501477 T	04-04-1991
		NZ 227003 A	26-11-1991
		PT 89118 A,B	01-12-1988
		US 5110819 A	05-05-1992
		ZA 8808763 A	26-07-1989
WO 8912629 A	28-12-1989	US 4918081 A	17-04-1990
WO 9222533 A	23-12-1992	JP 5213884 A	24-08-1993
		AU 2157192 A	12-01-1993
		MX 9202839 A	01-02-1993
EP 643045 A	15-03-1995	AT 190307 T	15-03-2000
		AU 683481 B	13-11-1997
		AU 7161794 A	23-03-1995
		CA 2131644 A	11-03-1995
		CN 1105991 A,B	02-08-1995
		CZ 9402187 A	15-03-1995
		DE 59409179 D	13-04-2000
		ES 2144501 T	16-06-2000
		FI 944120 A	11-03-1995
		HU 70556 A	30-10-1995
		JP 7179426 A	18-07-1995
		NO 943336 A	13-03-1995
		NZ 264420 A	25-06-1996
		SK 107394 A	10-05-1995
		US 5508408 A	16-04-1996
		ZA 9406957 A	18-04-1995
WO 9920275 A	29-04-1999	AU 9696198 A	10-05-1999
		EP 1030665 A	30-08-2000

INTERNATIONAL SEARCH REPORT

Information on patent family members

Internatio. Application No
PCT/US 00/11490

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9920275 A		NO 20001962 A	16-06-2000
		NO 20003107 A	26-07-2000